Annovis Bio Inc. - notizie pubblicate 164 - letture 2.980
ANNOVIS BIO INC.
New Listing Registration (Form 8-A12B)
United states securities and exchange commission washington, d.c. 20549 form 8-a for registration of certain classes of securities pursuant to section 12(b) or (g) of the securitie ...
ANNOVIS BIO INC.
November 15, 2021Annovis Bio Announces Transfer of Listing to the New York Stock Exchange
Mon, 15 nov 2021 trading to begin november 18, 2021 with current ticker "anvs" berwyn, pa., november 15, 2021 -- annovis bio, inc. (nyse american: anvs) ("annovis&qu ...
ANNOVIS BIO INC.
November 9, 2021Annovis Bio Presents Poster on Mechanism of Action at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Tue, 09 nov 2021 poster highlighting the mechanism of action for anvs401 is on display onsite and online berwyn, pa., november 9, 2021 -- annovis bio, inc. (nyse american: anvs) (& ...
ANNOVIS BIO INC.
Quarterly Report (Form 10-Q)
Table of contents united states securities and exchange commission washington, d.c. 20549 form 10-q ☒ quarterly report pursuant to section 13 or 15(d) of the securities exchange ...
ANNOVIS BIO INC.
Statement of Changes in Beneficial Ownership (Form 4)
The text version of this document is not available. you can access the original document here. attachments original document permalink disclaimer annovis bio inc. published this co ...
ANNOVIS BIO INC.
Statement of Changes in Beneficial Ownership (Form 4)
The text version of this document is not available. you can access the original document here. attachments original document permalink disclaimer annovis bio inc. published this co ...
ANNOVIS BIO INC.
Statement of Changes in Beneficial Ownership (Form 4)
The text version of this document is not available. you can access the original document here. attachments original document permalink disclaimer annovis bio inc. published this co ...
ANNOVIS BIO INC.
Annovis Bio Announces Positive Phase 2 Efficacy Data for the Treatment of Parkinson’s Disease (Form 8-K)
Annovis bio announces positive phase 2 efficacy data for the treatment of parkinson's disease data shows statistically significant improvements in speed and motor function in pd pa ...
ANNOVIS BIO INC.
September 24, 2021Annovis Bio to Present at the Cantor Global Healthcare Conference
Fri, 24 sep 2021 berwyn, pa., september 24, 2021 -- annovis bio, inc.(nyse american: anvs) ("annovis" or the "company"), a clinical-stage drug platform company ...
ANNOVIS BIO INC.
August 25, 2021Annovis Bio to Present at Biomarkers for Alzheimer’s Disease Summit 2021
Wed, 25 aug 2021 presentation will highlight positive biomarker data that corroborates the positive efficacy data from two phase 2 studies of anvs401 dr. maccecchini to present vir ...
ANNOVIS BIO INC.
Insider Trading Report (SEC Filing - 4)
Sec.gov | request rate threshold exceeded u.s. securities and exchange commission your request originates from an undeclared automated tool to allow for equitable access to all use ...
ANNOVIS BIO INC.
Quarterly Report (SEC Filing - 10-Q)
Table of contents united states securities and exchange commission washington, d.c. 20549 form 10-q ☒ quarterly report pursuant to section 13 or 15(d) of the securities exchange ...
ANNOVIS BIO INC.
June 3, 2021Annovis Bio to Present at Jefferies Virtual Healthcare Conference 2021
Thu, 03 jun 2021 berwyn, pennsylvania, june 3, 2021 - annovis bio, inc. (nyse american: anvs), ('annovis' or the 'company'), a clinical-stage drug platform company addressing alzhe ...
ANNOVIS BIO INC.
May 21, 2021Annovis Bio, Inc. Announces Proposed Public Offering of Common Stock
Fri, 21 may 2021 berwyn, pa - may 21, 2021- annovis bio, inc. (nasdaq: anvs) ('annovis' or the 'company') a clinical-stage drug platform company addressing alzheimer's disease (ad) ...
Per i consulenti finanziari
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti